Cynapsus Therapeutics Inc Stock

Stocks

Delayed Toronto S.E.			5-day change	1st Jan Change
- ^CAD	-.--%		+0.21%	-

Jun. 03	HyProMag Ltd is 100% Owned by Maginito Ltd, Which is Owned on a 79.4%/20.6% Basis by Mkango Resources and CoTec	MT
Jun. 03	HyProMag USA LLC is Owned 50:50 by CoTec and HyProMag Limited	MT

Jun. 03	HyProMag Ltd is 100% Owned by Maginito Ltd, Which is Owned on a 79.4%/20.6% Basis by Mkango Resources and CoTec	MT
Jun. 03	HyProMag USA LLC is Owned 50:50 by CoTec and HyProMag Limited	MT
Jun. 03	CoTec JV, HyProMag USA, to Commence Preparatory Work for Project Execution Phase at Dallas-Fort Worth Texas Hub	MT
May. 20	CoTec Releases Updated Mineral Resource and "Positive" PEA for Lac Jeannine Iron Tailings Project; Lost Near 10% on Tuesday	MT
24-03-11	Mkango and CoTec Brief: Mkango Subsidiary, Maginito, And CoTec Appointed Lead Engineers BBA And Pegasus To Complete Feasibility Study for HyProMag USA	MT
24-01-29	CoTec Holdings Outlines Key Targets For 2024	MT
24-01-03	Mkango Surges Near 12% As Forms HyProMag Joint Venture In US With CoTec	MT
23-10-10	Mkango Surges 11% As Says To Commence Feasibility Study For Proposed US Operation With CoTec	MT
23-10-10	Mkango, CoTec To Commence Feasibility Study For Proposed US Operation	MT
23-10-02	CoTec Completed Conversion of 2 Million Pounds Mkango Loan Note to Double Equity Position in Maginito to 20.6%	MT
23-09-14	Mkango Down Near 3% As Agrees To Form US Joint Venture With CoTec Holdings	MT
23-09-14	CoTec Holdings, Mkango To Form US Joint Venture	MT
23-06-30	Kings Chapel Increases Stake In CoTec Holdings	MT

May. 06	COPPER INTELLIGENCE TO FORM AN EARLY-STAGE EXPLORATION JOINT VENTURE WITH COTEC TO TARGET PROCESSING HISTORICAL COPPER TAILINGS OPPORTUNITIES IN THE DEMOCRATIC REPUBLIC OF CONGO	PR
16-08-31	Cynapsus Therapeutics : Sunovion Pharmaceuticals to Acquire Cynapsus Therapeutics	PU
16-08-29	Cynapsus Therapeutics : Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease	GL
16-08-15	Cynapsus Therapeutics : Announces Positive Opinion from Data and Safety Monitoring Board on Phase 3 Parkinson's Disease Clinical Study Allowing for At-Home Titration	GL
16-08-12	Cynapsus Therapeutics : Announces Publication in the Journal Movement Disorders of Data for the Treatment of OFF Episodes in Patients with Parkinson's Disease	GL

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CYNAPSUS THERAPEUTICS INC	-.--%	+0.21%	-	-	0
WUXI APPTEC CO., LTD.	-4.10%	-8.54%	+40.05%	+66.99%	63.29B
ARGENX SE	-0.41%	+3.27%	+10.46%	+72.82%	54.89B
LONZA GROUP AG	+0.74%	+4.04%	+12.18%	+88.71%	53.28B
IQVIA HOLDINGS INC.	+0.61%	+2.69%	+27.75%	+50.97%	45.81B
BEONE MEDICINES AG	-1.08%	+2.19%	+21.92%	+131.38%	43.46B
REVOLUTION MEDICINES, INC.	-3.39%	-0.83%	+254.27%	+571.04%	40.23B
CELLTRION, INC.	-1.67%	+6.70%	+14.42%	+56.67%	33.45B
WUXI BIOLOGICS (CAYMAN) INC.	+2.34%	-3.94%	+30.42%	+0.33%	23.7B
GENMAB A/S	+1.30%	+4.94%	+38.23%	+28.59%	23.76B
Average	-0.57%	+1.06%	+49.97%	+118.61%	42.43B
Weighted average by Cap.	-0.96%	+0.89%	+47.98%	+121.93%